2 citations
,
December 2024 in “Journal of Dermatological Treatment” IL-23 inhibitors, such as guselkumab, tildrakizumab, and risankizumab, are primarily approved for psoriasis but show potential for off-label use in treating various inflammatory skin conditions like hidradenitis suppurativa, lichen planus, and frontal fibrosing alopecia. While some case reports and small studies, including one with 69 patients with hidradenitis suppurativa, indicate significant improvements in symptoms and quality of life, the evidence remains limited. Larger, randomized clinical trials are needed to confirm the efficacy and safety of these inhibitors for off-label dermatologic uses. The safety profile is generally favorable, with upper respiratory tract infections being the most common side effect.
September 2025 in “Case Reports in Ophthalmology” Short-term use of topical minoxidil can cause eye issues, but stopping it can resolve the problem.
August 2022 in “IARS international research journal” The document concludes that drug repurposing, which is reusing known medicines for new illnesses, can provide faster, cheaper treatment options for various serious diseases, including cancer, COVID-19, and rare diseases.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
7 citations
,
December 2019 in “Pharmaceutics” Taking Dutasteride with Ketoconazole can increase Dutasteride's effects and side effects.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
Men with sexual side effects from finasteride may face higher risks of depression and suicidal thoughts.
1 citations
,
October 2025 in “Journal of Personalized Medicine” Weight loss improves PCOS symptoms and overall health.
June 2024 in “Military Medicine” Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.
June 2023 in “The Journal of Family Practice” The hair loss is likely due to a fade haircut.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
14 citations
,
January 2008 in “Dermatology Online Journal” Hormonal therapies like cyproterone acetate and spironolactone may help some women with hair loss, but finasteride 1mg is not useful, and the effectiveness of other treatments is still unclear.
6 citations
,
March 2022 in “Frontiers in drug discovery” Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.
December 2025 in “JMIR Dermatology” Topical finasteride is well-tolerated and satisfies most users with minimal side effects.
Most patients were satisfied with topical finasteride, and few experienced side effects.
August 2024 in “Journal of Clinical Medicine” Low-level laser therapy is the most supported treatment for hair loss, but other methods show promise.
January 2008 in “Dermatology Online Journal” Hormonal therapy like cyproterone acetate and spironolactone may help female hair loss, but more research is needed, especially for pre-menopausal women.
October 2023 in “Toxicology and Applied Pharmacology” Finasteride is more harmful to male reproductive health than minoxidil.
10 citations
,
February 2022 in “Cancers” More research and guidelines are needed for managing prostate cancer in people with high-risk genetic mutations.
5 citations
,
July 2023 in “International Journal of Women’s Dermatology” Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Many people in Jordan misuse topical steroids without proper knowledge, highlighting the need for better education and regulation.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
September 2022 in “Journal of Case Reports and Medical History” Many new moms lose hair after childbirth due to hormonal changes, but it usually grows back within a year.
10 citations
,
December 2014 in “PubMed” Finasteride, a hair loss drug, may cause sexual dysfunction and depression, but these effects are usually temporary and the drug is generally safe. More research is needed.
3 citations
,
January 2025 in “JID Innovations” Hidradenitis suppurativa tunnels worsen the disease and often need surgery because current treatments are not very effective.
December 2025 in “JEADV Clinical Practice” These new skin treatments are safer and more effective with minimal side effects.
October 2025 in “Infection Control and Hospital Epidemiology” Standardized protocols are crucial for safe and infection-free platelet-rich plasma therapy.
9 citations
,
March 2022 in “Antioxidants” Synthetic antioxidants are effective, cheap, and stable, with some like zinc and cholecalciferol reducing child and cancer deaths, but the safety of additives like BHA, BHT, TBHQ, and PEG needs more research.
November 2025 in “Free Radical Biology and Medicine” SOD1 and KL are promising targets for new hair loss treatments.
105 citations
,
April 2014 in “Trends in Pharmacological Sciences” Targeting the Smoothened receptor shows promise for treating certain cancers.